Biotechnology News and Research

RSS

SATAI invests $1.045 million in Azaya Therapeutics

SATAI (www.satai.us) and the South Texas Regional Center of Innovation and Commercialization (www.strcic.com) today announced an investment of $1.045 million in Azaya Therapeutics, Inc. through the Texas Emerging Technology Fund (ETF) for the commercialization of Azaya’s proprietary Protein Stabilized Nanoparticle (PSN) technology platform to produce targeted, safer and more effective formulations of chemotherapy pharmaceuticals for the treatment of cancer.

30 Sep 2009

Hitachi High-Technologies reaches milestone: More than 1000 units of TM-1000 shipped

Hitachi High-Technologies Corporation (TOKYO:8036) today announced that cumulative shipments of the tabletop microscope TM-1000, launched in April 2005, have now surpassed 1,000 units.

30 Sep 2009

Life Technologies Foundation awards grants for advancements in science

The Life Technologies Foundation, a non-profit arm of Life Technologies Corporation dedicated to advancing science education and scientific discovery, has awarded approximately $1.7 million in new grants that include the creation of an online biology textbook, and building a museum exhibit about the human cell.

30 Sep 2009

Michelle’s Miracle raises $750,000 in its first tranche of Series A funding

Michelle’s Miracle, Inc the leading provider of tart cherry nutraceutical products announced that it has closed its first tranche of Series A funding after raising approximately $750,000 in equity.

30 Sep 2009

AFRESA Inhalation Powder and AFRESA Inhaler NDA under FDA review

AFRESA® (insulin human [rDNA origin]) Inhalation Powder is a well-tolerated, ultra rapid acting insulin able to more closely replicate normal glucose suppression than currently available insulins, according to data presented at the 45th Annual Meeting of the European Association for the Study of Diabetes.

30 Sep 2009

China-Biotics to raise funds for working capital purposes

China-Biotics, Inc. (Nasdaq: CHBT) ("China-Biotics", "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced that it has priced a public offering of 4,600,000 shares of its common stock at $15.00 per share. The shares are being sold under the Company's previously filed shelf registration statement, which was declared effective by the Securities and Exchange Commission on September 9, 2009.

30 Sep 2009

MabCures develops monoclonal antibodies against Colorectal Cancer

MabCure, Inc., a biotechnology company that has developed a series of highly specific monoclonal antibodies (MAbs) to combat various types of cancers, has reached another development milestone, with the creation of its MAbs against Colorectal Cancer (CRC). After further characterization the company plans to explore the utility of these MAbs in terms of both the early diagnosis of CRC (in blood or feces specimens), as well as imaging agents for detecting micrometastatic disease during surgery and the detection of cancerous polyps during colonoscopy.

29 Sep 2009

pSivida reports interim results of human PK study of Iluvien

pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.

29 Sep 2009

Scarab Genomics releases new E. Coli strain

ScarabXpress is the latest strain in the multiple-deletion series (MDS) of Scarab Genomics Clean Genome® E. coli. Based on the MDS™42 strain, ScarabXpress T7lac contains a chromosomal copy of the T7 RNA polymerase gene expressed from a unique, tightly controlled lac promoter.

29 Sep 2009

Elan Corporation intends to offer senior fixed rate notes due 2016

Elan Corporation, plc today announced that its wholly-owned subsidiaries, Elan Finance public limited company and Elan Finance Corp., intend to offer, subject to market conditions, US$600 million in aggregate principal amount of senior fixed rate notes due 2016 (the “New Notes”).

29 Sep 2009

Biomagnetics Diagnostics to develop handheld testing platform for malaria and bovine TB

Biomagnetics Diagnostics Corp., a producer of revolutionary diagnostic systems and technology for malaria, tuberculosis, HIV and hepatitis testing today announced it has received a equity-based financing commitment up to $1 million from investors and an anonymous philanthropic source. These funds will be used to further develop the company’s unique handheld testing platform targeting the areas of malaria and bovine tuberculosis testing.

29 Sep 2009

Elan begins cash tender offer for $850 million in collective principal sum of 2011 Fixed Rate Notes

Elan Corporation, plc ("Elan") today announced that its wholly-owned subsidiaries, Elan Finance public limited company and Elan Finance Corp., are commencing a cash tender offer (the “Tender Offer”) for the outstanding US$850 million in aggregate principal amount of their 7 3/4% senior fixed rate notes due 2011 (the “2011 Fixed Rate Notes”).

29 Sep 2009

Patheon's special meeting of shareholders to be held as announced on December 15, 2009

The Special Committee of Independent Directors of Patheon Inc. announced that Joaquin Viso and Olga Lizardi have agreed to adjourn on consent the previously disclosed Court application they commenced on September 2, 2009 seeking an order requiring that a special meeting of shareholders (the "Requisitioned Meeting") in response to their previously announced requisition be held no later than October 30, 2009.

29 Sep 2009

Kane Biotech ends early exercise warrant incentive program

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and disperse microbial biofilms announces that the exercise period of the Company's early exercise warrant incentive program (the "Program") has ended. The Program was previously announced in the Company's press release dated August 6, 2009.

29 Sep 2009

Biochemistry professor to discuss controversies in dietary strategies in diabetes treatment

Richard Feinman, PhD, professor of biochemistry and of family medicine at SUNY Downstate Medical Center in Brooklyn, New York, will speak at the annual conference of the European Association for the Study of Diabetes (EASD) on October 2, 2009. EASD is holding its annual conference September 28 - October 2 in Vienna, Austria.

29 Sep 2009

Ligand and GSK amend agreement to pursue independent research programs

Ligand Pharmaceuticals Incorporated today announced that pursuant to an amendment to a March 2006 research agreement with GlaxoSmithKline, GSK has agreed to accelerate the timing of a $500,000 payment to Ligand that would otherwise have been required upon the identification of a new lead chemical series for advancement in its alliance with GSK.

29 Sep 2009

NHGRI announces grant to establish Wisconsin Center of Excellence in Genomics Science

The National Human Genome Research Institute (NHGRI) of the National Institutes of Health today announced an $8 million, three-year grant to establish a Wisconsin Center of Excellence in Genomics Science.

29 Sep 2009

Kane Biotech's Dispersinb Topical Wound Gel passes cytotoxicity and primary skin irritation tests

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and remove microbial biofilms is pleased to announce that DispersinB® Topical Wound Gel has passed the FDA-recommended Cytotoxicity and Primary Skin Irritation tests conducted by WuXi AppTec Inc. (St. Paul, MN) in compliance with Good Laboratory Practice (GLP). Thus, DispersinB® wound gel is considered non-cytotoxic and non-irritant.

28 Sep 2009

NIH awards DiscoveryBioMed a Phase 2 SBIR grant for research on hypertension and cystic fibrosis

DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a $750,000 Small Business Innovations Research (SBIR) Phase 2 grant by the National Institutes of Health (NIH) to continue the research into the discovery and development of small molecules to alleviate multiple chronic human diseases including cystic fibrosis (CF), hypertension and chronic kidney diseases with hypertension.

28 Sep 2009

PolyMedix receives patent protection for computational methods in the design of amphiphilic polymers

PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has received patent protection for certain exclusively licensed intellectual property by the issuance to the University of Pennsylvania of U.S. patent number 7,590,517, “Methods, Systems, and Computer Program Products for Computational Design of Amphiphilic Polymers.”

28 Sep 2009

Biotechnology News and Research

SATAI invests $1.045 million in Azaya Therapeutics

Hitachi High-Technologies reaches milestone: More than 1000 units of TM-1000 shipped

Life Technologies Foundation awards grants for advancements in science

Michelle’s Miracle raises $750,000 in its first tranche of Series A funding

AFRESA Inhalation Powder and AFRESA Inhaler NDA under FDA review

China-Biotics to raise funds for working capital purposes

MabCures develops monoclonal antibodies against Colorectal Cancer

pSivida reports interim results of human PK study of Iluvien

Scarab Genomics releases new E. Coli strain

Elan Corporation intends to offer senior fixed rate notes due 2016

Biomagnetics Diagnostics to develop handheld testing platform for malaria and bovine TB

Elan begins cash tender offer for $850 million in collective principal sum of 2011 Fixed Rate Notes

Patheon's special meeting of shareholders to be held as announced on December 15, 2009

Kane Biotech ends early exercise warrant incentive program

Biochemistry professor to discuss controversies in dietary strategies in diabetes treatment

Ligand and GSK amend agreement to pursue independent research programs

NHGRI announces grant to establish Wisconsin Center of Excellence in Genomics Science

Kane Biotech's Dispersinb Topical Wound Gel passes cytotoxicity and primary skin irritation tests

NIH awards DiscoveryBioMed a Phase 2 SBIR grant for research on hypertension and cystic fibrosis

PolyMedix receives patent protection for computational methods in the design of amphiphilic polymers

Biotechnology eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News